Alector (ALEC) recently reported that its experimental therapy latozinemab did not meet the main efficacy goal in a late-stage trial for frontotemporal dementia. As a result, multiple follow-up ...

Alector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like ...

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

Alector stock has experienced a notable shift in analyst sentiment after recent program setbacks, as reflected in the consensus analyst price target dropping from $3.83 to $2.20 per share. This sharp ...

The immediate consequences of the disappointing result are a big reduction in workforce at South San Francisco-based Alector, ...

Alector (ALEC) stock drops after a Phase 3 trial failure for a dementia drug it was developing with GSK (GSK). Read more here ...

Fintel reports that on October 22, 2025, BTIG downgraded their outlook for Alector (NasdaqGS:ALEC) from Buy to Neutral.

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

Alector Inc. cuts its workforce by nearly 50% following the failure of its dementia drug trial, signalling challenges in the ...

An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage ...

Fintel reports that on October 22, 2025, HC Wainwright & Co. maintained coverage of Alector (NasdaqGS:ALEC) with a Buy ...